Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accounts Payables (2016 - 2025)

Agios Pharmaceuticals' Accounts Payables history spans 14 years, with the latest figure at $18.4 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 10.29% year-over-year to $18.4 million; the TTM value through Dec 2025 reached $18.4 million, up 10.29%, while the annual FY2025 figure was $18.4 million, 10.29% up from the prior year.
  • Accounts Payables reached $18.4 million in Q4 2025 per AGIO's latest filing, down from $19.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $51.2 million in Q1 2021 to a low of $7.7 million in Q2 2021.
  • Average Accounts Payables over 5 years is $15.1 million, with a median of $12.4 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: skyrocketed 173.82% in 2021, then plummeted 77.45% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $16.7 million in 2021, then increased by 11.47% to $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then skyrocketed by 70.17% to $16.6 million in 2024, then grew by 10.29% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Accounts Payables are $18.4 million (Q4 2025), $19.6 million (Q3 2025), and $17.5 million (Q2 2025).